Published in Int J Hematol on April 05, 2012
Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project. Blood (2013) 1.69
A variational Bayes discrete mixture test for rare variant association. Genet Epidemiol (2014) 0.92
Secretion of von Willebrand factor by endothelial cells links sodium to hypercoagulability and thrombosis. Proc Natl Acad Sci U S A (2014) 0.85
Emerging Roles of ADAMTSs in Angiogenesis and Cancer. Cancers (Basel) (2012) 0.80
On the versatility of von Willebrand factor. Mediterr J Hematol Infect Dis (2013) 0.78
Combined genetic effects of EGLN1 and VWF modulate thrombotic outcome in hypoxia revealed by Ayurgenomics approach. J Transl Med (2015) 0.78
A factor VIII-derived peptide enables von Willebrand factor (VWF)-binding of artificial platelet nanoconstructs without interfering with VWF-adhesion of natural platelets. Nanoscale (2014) 0.76
Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions. Mediterr J Hematol Infect Dis (2013) 0.75
Conventional rapid latex agglutination in estimation of von Willebrand factor: method revisited and potential clinical applications. J Immunol Res (2014) 0.75
Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A (2010) 5.69
Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med (2003) 5.33
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med (1982) 4.05
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet (1995) 4.01
Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science (2009) 3.85
Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost (2012) 3.39
Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A (2007) 3.24
Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med (2002) 3.04
Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet (1992) 2.95
von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood (2010) 2.82
Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation (2010) 2.78
The complex multimeric composition of factor VIII/von Willebrand factor. Blood (1981) 2.76
Histones induce rapid and profound thrombocytopenia in mice. Blood (2011) 2.66
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol (2000) 1.81
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood (2002) 1.78
Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report. Arterioscler Thromb Vasc Biol (2010) 1.74
Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood (2009) 1.70
Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions. J Thromb Haemost (2008) 1.68
Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. Blood (2011) 1.66
Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood (2009) 1.65
Disulfide bond reduction of von Willebrand factor by ADAMTS-13. J Thromb Haemost (2010) 1.59
von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol (1999) 1.57
Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction. Circulation (2008) 1.56
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood (2008) 1.54
Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation (2000) 1.48
von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood (2006) 1.44
How I treat the acquired von Willebrand syndrome. Blood (2011) 1.36
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood (2005) 1.35
Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood (2011) 1.33
Biology and physics of von Willebrand factor concatamers. J Thromb Haemost (2011) 1.33
N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest (2011) 1.32
Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost (2007) 1.31
Platelet adhesion under flow. Microcirculation (2009) 1.31
Von Willebrand factor: molecular size and functional activity. Ann Hematol (1996) 1.26
Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost (2001) 1.25
An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem (2003) 1.21
Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood (2009) 1.18
Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood (2010) 1.17
Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood (1986) 1.16
Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost (2005) 1.14
Hematologic effects of continuous flow left ventricular assist devices. J Cardiovasc Transl Res (2010) 1.13
ADAMTS13 turns 3. Blood (2005) 1.13
Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia (2008) 1.13
Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost (2011) 1.10
Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost (2010) 1.10
Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood (2008) 1.05
Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood (1993) 1.04
Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels. BMC Med Genet (2011) 1.02
New variant of von Willebrand disease with defective binding to factor VIII. Blood (1989) 1.02
Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet (2010) 1.01
von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. J Thromb Haemost (2011) 1.01
Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood (2010) 0.99
Regulation of von Willebrand factor-platelet interactions. Thromb Haemost (2010) 0.92
beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood (2007) 0.90
Molecular and cellular biology of von Willebrand factor. Int J Hematol (2002) 0.89
Clearance of von Willebrand factor. Thromb Haemost (2008) 0.89
Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J Thromb Haemost (2006) 0.89
Von Willebrand factor: drug and drug target. Cardiovasc Hematol Disord Drug Targets (2009) 0.89
Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med (2009) 0.89
Critical role of von Willebrand factor and platelet interaction in venous thromboembolism. Histol Histopathol (2009) 0.88
Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood (2009) 0.88
Association between high von willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. The GENEDIAB Study Group and the DESIR Study Group. Kidney Int (2000) 0.88
Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. Blood (2011) 0.88
Impact of the Thr789Ala variant of the von Willebrand factor levels, on ristocetin co-factor and collagen binding capacity and its association with coronary heart disease in patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes (2005) 0.88
Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost (2011) 0.87
Pathophysiology of acquired von Willebrand disease: a concise review. Eur J Haematol (2011) 0.85
Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis. J Biol Chem (2011) 0.84
Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. Biochem J (2012) 0.81
Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol (1990) 0.81
Phenotypic and genotypic diagnosis of von Willebrand disease: a 2004 update. Semin Hematol (2005) 0.79
Hypothesis for control of von Willebrand factor multimer size by intra-molecular thiol-disulphide exchange. J Thromb Haemost (2006) 0.79
Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol (2004) 0.77
Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost (2011) 0.77
ADAMTS-13: double trouble for von Willebrand factor. J Thromb Haemost (2010) 0.76
Angiodysplasia associated with hypertrophic obstructive cardiomyopathy (HOCM). Br J Clin Pract (1990) 0.76
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med (2007) 2.32
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension (2008) 1.95
Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler Thromb Vasc Biol (2007) 1.85
Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood (2008) 1.72
Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica (2005) 1.63
New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One (2010) 1.59
Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med (2006) 1.56
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood (2008) 1.54
A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood (2009) 1.51
Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood (2013) 1.51
Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A (2008) 1.51
Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood (2007) 1.47
Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis (2007) 1.42
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood (2013) 1.36
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood (2005) 1.35
Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem (2005) 1.34
The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood (2011) 1.24
P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood (2006) 1.24
Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem (2003) 1.20
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood (2006) 1.20
Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem (2003) 1.16
The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol (2007) 1.16
Staphylococcus aureus protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. FEBS J (2006) 1.13
The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction. J Immunol (2008) 1.07
Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood (2008) 1.05
LDL-receptor-related protein regulates beta2-integrin-mediated leukocyte adhesion. Blood (2004) 1.04
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol (2008) 1.02
Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood (2010) 0.99
The alpha -chains of C4b-binding protein mediate complex formation with low density lipoprotein receptor-related protein. J Biol Chem (2001) 0.97
von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate. Blood (2003) 0.96
Binding of low density lipoprotein to platelet apolipoprotein E receptor 2' results in phosphorylation of p38MAPK. J Biol Chem (2004) 0.94
Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood (2003) 0.93
Of von Willebrand factor and platelets. Cell Mol Life Sci (2014) 0.93
Functional duplication of ligand-binding domains within low-density lipoprotein receptor-related protein for interaction with receptor associated protein, alpha2-macroglobulin, factor IXa and factor VIII. Biochim Biophys Acta (2007) 0.92
Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J Biol Chem (2003) 0.92
von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3. J Clin Invest (2013) 0.91
Residues Phe342-Asn346 of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein. J Biol Chem (2003) 0.90
beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood (2007) 0.90
Clearance of von Willebrand factor. Thromb Haemost (2008) 0.89
Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants. Arterioscler Thromb Vasc Biol (2008) 0.87
In vivo analysis of the role of O-glycosylations of von Willebrand factor. PLoS One (2012) 0.87
Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS One (2009) 0.87
Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity. PLoS One (2011) 0.87
Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood (2012) 0.86
Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica (2012) 0.86
Mouse leukocyte-associated Ig-like receptor-1 (mLAIR-1) functions as an inhibitory collagen-binding receptor on immune cells. Int Immunol (2007) 0.85
Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood (2006) 0.85
Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor. Arterioscler Thromb Vasc Biol (2012) 0.81
Cellular uptake of C4b-binding protein is mediated by heparan sulfate proteoglycans and CD91/LDL receptor-related protein. Eur J Immunol (2008) 0.80
A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor. Blood (2012) 0.80
Beta2-glycoprotein I and LDL-receptor family members. Thromb Res (2004) 0.80
A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis. Thromb Haemost (2016) 0.80
Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF. Blood (2007) 0.80
Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood (2013) 0.79
In vivo clearance of human protein S in a mouse model: influence of C4b-binding protein and the Heerlen polymorphism. Arterioscler Thromb Vasc Biol (2005) 0.78
On the versatility of von Willebrand factor. Mediterr J Hematol Infect Dis (2013) 0.78
The connecting segment between both epidermal growth factor-like domains in blood coagulation factor IX contributes to stimulation by factor VIIIa and its isolated A2 domain. J Biol Chem (2002) 0.77
Active von Willebrand factor and the risk of stroke. Atherosclerosis (2009) 0.77
Co-expression of the collagen receptors leukocyte-associated immunoglobulin-like receptor-1 and glycoprotein VI on a subset of megakaryoblasts. Haematologica (2010) 0.76
Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions. Mediterr J Hematol Infect Dis (2013) 0.75
Coagulation factor X interaction with macrophages through its N-glycans protects it from a rapid clearance. PLoS One (2012) 0.75
Antibody-Based Protection of von Willebrand Factor Degradation. JACC Heart Fail (2016) 0.75